Search Results Search Sort by RelevanceMost Recent Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029. Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036. Policy Forum Dec 2019 Why Include the Public in Genome Editing Governance Deliberation? Alessandro Blasimme, PhD International debate about human genome editing governance has undergone a paradigm shift and suggests that inclusive public deliberation is still important. AMA J Ethics. 2019;21(12):E1065-1070. doi: 10.1001/amajethics.2019.1065. Viewpoint Dec 2019 Genome Editing, Ethics, and Politics Isabel Gabel, PhD and Jonathan Moreno, PhD Genome editing raises old questions, but CRISPR arose in a political landscape that vastly differs from the early aughts. AMA J Ethics. 2019;21(12):E1105-1110. doi: 10.1001/amajethics.2019.1105. Medicine and Society Feb 2017 The Case of Dr. Oz: Ethics, Evidence, and Does Professional Self-Regulation Work? Jon C. Tilburt, MD, MPH, Megan Allyse, PhD, and Frederic W. Hafferty, PhD Dr. Oz’s advice has raised ethical questions about medicine as a profession, its evidentiary standards, and its role in maintaining public trust. AMA J Ethics. 2017;19(2):199-206. doi: 10.1001/journalofethics.2017.19.2.msoc1-1702. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600. Medical Education Sep 2019 Which LCME Accreditation Expectations Support Quality and Safety in Global Health Immersion Experiences for Medical Students? Robert Hash, MD, MBA and Barbara Barzansky, PhD, MHPE Almost all allopathic medical schools in the United States allow students to participate in global health. AMA J Ethics. 2019;21(9):E766-771. doi: 10.1001/amajethics.2019.766. Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029.
Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036.
Policy Forum Dec 2019 Why Include the Public in Genome Editing Governance Deliberation? Alessandro Blasimme, PhD International debate about human genome editing governance has undergone a paradigm shift and suggests that inclusive public deliberation is still important. AMA J Ethics. 2019;21(12):E1065-1070. doi: 10.1001/amajethics.2019.1065.
Viewpoint Dec 2019 Genome Editing, Ethics, and Politics Isabel Gabel, PhD and Jonathan Moreno, PhD Genome editing raises old questions, but CRISPR arose in a political landscape that vastly differs from the early aughts. AMA J Ethics. 2019;21(12):E1105-1110. doi: 10.1001/amajethics.2019.1105.
Medicine and Society Feb 2017 The Case of Dr. Oz: Ethics, Evidence, and Does Professional Self-Regulation Work? Jon C. Tilburt, MD, MPH, Megan Allyse, PhD, and Frederic W. Hafferty, PhD Dr. Oz’s advice has raised ethical questions about medicine as a profession, its evidentiary standards, and its role in maintaining public trust. AMA J Ethics. 2017;19(2):199-206. doi: 10.1001/journalofethics.2017.19.2.msoc1-1702.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600.
Medical Education Sep 2019 Which LCME Accreditation Expectations Support Quality and Safety in Global Health Immersion Experiences for Medical Students? Robert Hash, MD, MBA and Barbara Barzansky, PhD, MHPE Almost all allopathic medical schools in the United States allow students to participate in global health. AMA J Ethics. 2019;21(9):E766-771. doi: 10.1001/amajethics.2019.766.